Cargando…

Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer

BACKGROUND: Circulating total cytokeratin 18 (tCK18) and/or caspase cleaved cytokeratin 18 (cCK18) (measured by M65 and M30 enzyme-linked immunosorbent assays (ELISAs), respectively) are used as pharmacodynamic (PD) biomarkers of epithelial cell death in clinical trials. Having validated these ELISA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Greystoke, A, Dean, E, Saunders, M P, Cummings, J, Hughes, A, Ranson, M, Dive, C, Renehan, A G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493762/ https://www.ncbi.nlm.nih.gov/pubmed/22996610 http://dx.doi.org/10.1038/bjc.2012.416

Ejemplares similares

Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma
por: Greystoke, A, et al.
Publicado: (2011)

Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs
por: Brookes, K, et al.
Publicado: (2010)

A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker
por: Khoja, L, et al.
Publicado: (2012)

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study
por: Board, R E, et al.
Publicado: (2009)

Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients
por: Wong, S C C, et al.
Publicado: (2011)

Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab
por: Zhou, Cong, et al.
Publicado: (2016)

Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours
por: Weidlich, S, et al.
Publicado: (2011)

Prognostic value of circulating tumour cells for early recurrence after resection of colorectal liver metastases
por: Lalmahomed, Z S, et al.
Publicado: (2015)

Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours
por: Sefrioui, David, et al.
Publicado: (2017)

PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness
por: Molleví, D G, et al.
Publicado: (2008)

Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients
por: Winther-Larsen, Anne, et al.
Publicado: (2017)

Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype
por: Ameri, K, et al.
Publicado: (2010)

Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer
por: Ankeny, J S, et al.
Publicado: (2016)

Monitoring gastric cancer progression with circulating tumour DNA
por: Hamakawa, T, et al.
Publicado: (2015)

A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei
por: Bibi, R, et al.
Publicado: (2006)

Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours
por: Childs, Alexa, et al.
Publicado: (2016)

Dichloroacetate induces autophagy in colorectal cancer cells and tumours
por: Lin, G, et al.
Publicado: (2014)

Circulating tumour markers can define patients with normal colons, benign polyps, and cancers
por: Mead, R, et al.
Publicado: (2011)

Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment
por: Slade, M J, et al.
Publicado: (2009)

DNA Methylation in Circulating Tumour DNA as a Biomarker for Cancer
por: Board, Ruth E, et al.
Publicado: (2008)

Tumour-suppressive function of SIRT4 in human colorectal cancer
por: Miyo, M, et al.
Publicado: (2015)

Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer
por: Dive, C, et al.
Publicado: (2010)

Circulating IL-6 concentrations link tumour necrosis and systemic and local inflammatory responses in patients undergoing resection for colorectal cancer
por: Guthrie, G J K, et al.
Publicado: (2013)

Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope
por: Ntouroupi, T G, et al.
Publicado: (2008)

Tumour-site-dependent expression profile of angiogenic factors in tumour-associated stroma of primary colorectal cancer and metastases
por: Kahlert, C, et al.
Publicado: (2014)

The in situ local immune response, tumour senescence and proliferation in colorectal cancer
por: Roxburgh, C S, et al.
Publicado: (2013)

Secreted semaphorin 5A suppressed pancreatic tumour burden but increased metastasis and endothelial cell proliferation
por: Sadanandam, A, et al.
Publicado: (2012)

Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation
por: Skvortsova, T E, et al.
Publicado: (2006)

Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancer
por: Peeters, D J E, et al.
Publicado: (2011)

Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer
por: Rogers, A C, et al.
Publicado: (2016)

Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity
por: Wilson, G R, et al.
Publicado: (2006)

Tumour microenvironment of both early- and late-stage colorectal cancer is equally immunosuppressive
por: O'Toole, A, et al.
Publicado: (2014)

CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a ‘pro-/anti-tumour’ approach to tumour host interaction in colorectal cancer
por: Lugli, A, et al.
Publicado: (2009)

Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer
por: Ngan, C Y, et al.
Publicado: (2007)

KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer
por: Kawamoto, Y, et al.
Publicado: (2012)

Beclin 1 over- and underexpression in colorectal cancer: distinct patterns relate to prognosis and tumour hypoxia
por: Koukourakis, M I, et al.
Publicado: (2010)

A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer
por: Molloy, T J, et al.
Publicado: (2011)

Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes
por: Peeters, D J E, et al.
Publicado: (2014)

High levels of cleaved caspase-3 in colorectal tumour stroma predict good survival
por: Noble, P, et al.
Publicado: (2013)

Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer
por: Flores, L M, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_nbou4d3mglbfakb9uui3vjakur